NRX-101

Phase 3Small molecule

NNeuroRx, Inc.

NRX-101 is one of 38 small molecule programs targeting Major Depression. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major DepressionNot yet recruiting

Treatment Resistant DepressionNot yet recruiting

Major DepressionPhase 1

Not yet recruiting

Treatment Resistant DepressionPhase 3

Not yet recruiting

Competition

Competitive Landscape

32 competitors in Treatment Resistant Depression

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

24 2

Spravato

WWim Janssens

Approved

15 3

Risperdal

WWim Janssens

Approved

5 4

Lithobid

SSolvay Pharmaceuticals

Approved

4 5

Bayer Aspirin

Abilify

3 7

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Approved

3 8

Wellbutrin

GGlaxo Dba Glaxosmithkline

Approved

2 9

Mirapex

Boehringer Ingelheim

Approved

2 10

Gocovri

GGrupo Espanol de Tumores Neuroendocrinos

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Major Depression

NCT07785102

Q1 2028

PreclinicalNot yet recruiting

Treatment Resistant Depression

NCT07227103

Clinical

Trials by Indication[1]

Suicidal Ideation2 trials

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

Unknown status·NNeuroRx, Inc.·Phase 3·NCT03396068·72 enrolled

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

Completed·NNeuroRx, Inc.·Phase 2/3·NCT03395392·74 enrolled

Treatment Resistant Depression2 trials

NRX-101 for Treatment-Resistant Depression in Patients Receiving Transcranial Magnetic Stimulation Who Do Not Qualify for NRX101-011 (MIND1): Expanded Access Program

Available·NNeuroRx, Inc.··NCT05779267

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

Not yet recruiting·NNeuroRx, Inc.·Preclinical·NCT07227103·400 enrolled

Biomarker1 trial

NRX101 Glx Biomarker Validation Study

Completed·NNeuroRx, Inc.·Phase 2/3·NCT03402152·8 enrolled

Bipolar Depression1 trial

Sequential Therapy for the Treatment of Severe Bipolar Depression.

Completed·NNeuroRx, Inc.·Phase 2·NCT02974010·22 enrolled

Major Depression1 trial

SPARC-LI: Synaptic Plasticity Augmented Rapid Circuit Stimulation

Not yet recruiting·MMclean Hospital·Phase 1·NCT07785102·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for NRX-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NRX-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NRX-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NeuroRx, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNeuroRx, Inc.

NRX-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Trials by Indication[1]

Suicidal Ideation2 trials

Treatment Resistant Depression2 trials

Biomarker1 trial

Bipolar Depression1 trial

Major Depression1 trial

References

Drug Info

Quick Facts

Related News